Neuland Laboratories Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Neuland Laboratories heeft een totaal eigen vermogen van ₹14.0B en een totale schuld van ₹941.5M, wat de schuld-eigenvermogensverhouding op 6.7% brengt. De totale activa en totale passiva bedragen respectievelijk ₹19.4B en ₹5.5B. De EBIT Neuland Laboratories is ₹3.5B waardoor de rentedekking -5315.1 is. Het heeft contanten en kortetermijnbeleggingen van ₹1.9B.

Belangrijke informatie

6.7%

Verhouding schuld/eigen vermogen

₹941.46m

Schuld

Rente dekkingsratio	-5315.1x
Contant	₹1.90b
Aandelen	₹13.95b
Totaal verplichtingen	₹5.49b
Totaal activa	₹19.44b

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Neuland Laboratories (NSE:NEULANDLAB) Is Using Debt Reasonably Well

Dec 05

Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly

Aug 30

Recent updates

Investors Appear Satisfied With Neuland Laboratories Limited's (NSE:NEULANDLAB) Prospects As Shares Rocket 28%

Dec 08

These 4 Measures Indicate That Neuland Laboratories (NSE:NEULANDLAB) Is Using Debt Reasonably Well

Dec 05

Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance

Nov 14

Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Nov 09

Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching

Nov 08

After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar

Oct 17

Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up

Aug 22

Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?

Aug 02

Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00

Jul 12

Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking

Jul 02

Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's

Jun 19

Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?

Jun 12

Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00

May 21

There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump

Apr 19

We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease

Apr 15

Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%

Feb 17

Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates

Feb 12

Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly

Jan 05

The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount

Nov 12

Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today

Oct 27

Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly

Aug 24

Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically

Aug 05

Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00

Jul 05

Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00

Jun 21

Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00

May 14

Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?

May 12

Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly

Aug 30

I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut

Feb 23

The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically

Feb 03

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹9.7B ) NEULANDLAB } overtreffen de korte termijn passiva ( ₹4.1B ).

Langlopende schulden: De kortetermijnactiva NEULANDLAB ( ₹9.7B ) overtreffen de langetermijnschulden ( ₹1.4B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: NEULANDLAB heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van NEULANDLAB is de afgelopen 5 jaar gedaald van 28.1% naar 6.7%.

Schuldendekking: De schuld van NEULANDLAB wordt goed gedekt door de operationele kasstroom ( 261% ).

Rentedekking: NEULANDLAB verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Balans

Ontdek gezonde bedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/08 12:50
Aandelenkoers aan het einde van de dag	2025/01/08 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Neuland Laboratories Limited wordt gevolgd door 5 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Srivathsan Ramachandran	Avendus Spark
Rohit Bhat	Batlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. Chavali	FirstCall Research

Neuland Laboratories Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Neuland Laboratories (NSE:NEULANDLAB) Is Using Debt Reasonably Well

Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?

Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly

Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly

Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly

Recent updates

Investors Appear Satisfied With Neuland Laboratories Limited's (NSE:NEULANDLAB) Prospects As Shares Rocket 28%

These 4 Measures Indicate That Neuland Laboratories (NSE:NEULANDLAB) Is Using Debt Reasonably Well

Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance

Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching

Second quarter 2025 earnings released: EPS: ₹25.60 (vs ₹69.56 in 2Q 2024)

Neuland Laboratories Limited to Report Q2, 2025 Results on Nov 06, 2024

After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar

Price target increased by 37% to ₹16,875

Investor sentiment improves as stock rises 18%

Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up

New minor risk - Share price stability

Price target increased by 14% to ₹9,450

Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?

Neuland Laboratories Limited Approves Final Dividend for the Financial Year 2023-24

Neuland Laboratories Limited to Report Q1, 2025 Results on Aug 01, 2024

Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00

Full year 2024 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of ₹14.00 per share

Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 15%

Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's

Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?

Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00

Dividend increased to ₹14.00

Neuland Laboratories Limited, Annual General Meeting, Jul 31, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Neuland Laboratories Limited Recommends Final Dividend for the Financial Year 2023-24

Neuland Laboratories Limited Announces Bharati Rao Cease to Be A as an Independent Director

Neuland Laboratories Limited to Report Q4, 2024 Results on May 10, 2024

There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump

Investor sentiment improves as stock rises 18%

We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease

Investor sentiment deteriorates as stock falls 16%

Neuland Laboratories Limited Announces Appointment of Ashutosh Kumar Sinha as Chief Quality Officer

Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%

Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates

Third quarter 2024 earnings released: EPS: ₹63.44 (vs ₹23.81 in 3Q 2023)

Neuland Laboratories Limited to Report Q3, 2024 Results on Feb 08, 2024

Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly

Neuland Laboratories Limited Announces the Appointment of Dr. Sharadsrikar V.Kotturi as Chief Scientific Officer

The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount

Second quarter 2024 earnings released: EPS: ₹69.56 (vs ₹29.97 in 2Q 2023)

Investor sentiment improves as stock rises 19%

Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today

Neuland Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Neuland Laboratories Limited Announces Resignation of Humayun Dhanrajgir as Independent Director

Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly

Price target increased by 52% to ₹3,800

Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically

Neuland Laboratories Limited Approves Final Dividend for the Financial Year 2022-23

Neuland Laboratories Limited to Report Q1, 2024 Results on Aug 03, 2023

Neuland Laboratories Limited to Report Q1, 2024 Results on Aug 03, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00

Upcoming dividend of ₹10.00 per share at 0.3% yield

Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00

Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00

Neuland Laboratories Limited, Annual General Meeting, Jul 27, 2023

Price target increased by 28% to ₹2,280

Neuland Laboratories Limited Recommends Final Dividend for the Financial Year 2022-23

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?

Investor sentiment improves as stock rises 25%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: ₹23.81 (vs ₹10.08 in 3Q 2022)

Neuland Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023

Neuland Laboratories Limited Announces Appointment of Abhijit Majumdar as CFO

Insufficient new directors